Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention
18 Abril 2024 - 6:00AM
UK Regulatory
Smith+Nephew announces new evidence supporting ALLEVYN LIFE
Foam Dressing’s role in pressure injury prevention
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology
company is pleased to announce exciting data for its ALLEVYN LIFE
Dressing in a recent study by Professor Amit Gefen and his research
group published in the International Wound
Journal,1 that shows a novel mechanism of action
relating to pressure injury prevention (PIP).
The study found that due to the independent and non-bonded
internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding
phenomenon occurs and allows for dissipation of mechanical energy
that could otherwise be transferred to the patient in a bonded
dressing.1
The results show that layer-on-layer frictional sliding of
ALLEVYN LIFE Dressing absorbs 30-45% of the mechanical energy,
which could help alleviate pressure injury incidence in a patient's
skin and underlying soft tissues. This novel mechanism of action
further adds to our understanding of how multi-layer dressings such
as ALLEVYN LIFE work when used prophylactically for
PIP.1
“Based on my extensive, decades-long research in pressure
ulcer/injury prevention, I am certain that an effective prevention
dressing must contain a shear mitigation mechanism,” said Amit
Gefen, Professor of Biomedical Engineering at Tel Aviv University.
“My recent study published in the International Wound
Journal on ALLEVYN LIFE Dressing revealed the role of its
unique internal frictional layer-on-layer sliding which, together
with its specific construct and material composition, facilitate
effective shear mitigation.”
“Pressure injuries have a high burden on patients and healthcare
systems,” said Rohit Kashyap, President, Advanced Wound Management
at Smith+Nephew. “This alignment of the laboratory findings with
the clinical literature clearly demonstrates the enhanced clinical
efficacy of ALLEVYN LIFE Dressings in helping reduce the burden of
preventable pressure injuries as one of the only 5-layer foam
dressings with independent, non-bonded layers.”
Pressure injuries remain one of the most significant healthcare
challenges globally that affects patients of all ages.1
On average, a pressure injury leads to increased healthcare costs
of $21,767 per patient and an extra 9.5 days in
hospital.8
The study introduced a novel method to thoroughly test the
frictional sliding capabilities of the independent layers of
ALLEVYN LIFE Dressing. A new metric, frictional energy absorber
effectiveness (FEAE), was also introduced to quantify the total
mechanical energy dissipation of ALLEVYN LIFE
Dressing.1
This newly discovered mechanism of action for ALLEVYN LIFE
Dressing further adds, and gives context to, the already existing
wealth of clinical evidence9 for its capabilities in PIP
that demonstrate significant reduction in pressure injury
incidence.*1
To read the full publication please click here. To learn more
about ALLEVYN LIFE Foam Dressings please click here.
- ends -
Enquiries
Media |
|
Dave Snyder |
+1 978-749-1440 |
Smith+Nephew |
|
|
|
*For category II and above pressure injuries, when
applied prophylactically in combination with a standard PIP
protocol, versus standard protocols alone
References
- Marché C, Creehan S, Gefen A. The frictional energy absorber
effectiveness and its impact on the pressure ulcer prevention
performance of multilayer dressings. Int Wound J. 2024;
21(4):e14871.
- Smith+Nephew 2016. Permeability of Hydrophillic Polyurethane
Film when in contact with water and water vapour (ALLEVYN LIFE).
Internal Report. RD/16/019.
- Tiscar-González V, Menor-Rodríguez MJ, Rabadán-Sainz C, et al.
Clinical and Economic Impact of Wound Care Using a Polyurethane
Foam Multilayer Dressing. Adv Skin Wound Care.
2021;34(1):23–30.
- Smith+Nephew 2016. Wound Model Testing of New ALLEVYN Life Gen2
wcl Dressing using Horse Serum at a Flow Rate Modelling that of a
Moderately Exuding Wound. DS/14/303/R
- Rossington A, Drysdale K, Winter R. Clinical performance and
positive impact on patient wellbeing of ALLEVYN Life. Wounds
UK. 2013;9(4):91–95
- Clarke R. Positive patient outcomes: The use of a new silicone
adhesive foam dressing for pressure ulcer prevention and treatment.
Paper presented at: CAET; 2013
- Lisco C. Evaluation of a new silicone gel-adhesive
hydrocellular foam dressing as part of a pressure ulcer prevention
plan for ICU patients. Paper presented at: WOCN; 2013
- Wassel C, Delhougne G, Gayle J, et al. Risk of readmissions,
mortality, and hospital-acquired conditions across
hospital-acquired pressure injury (HAPI) stages in a US National
Hospital discharge database. Int Wound J. 2020; 1–11.
- Smith+Nephew 2021. ALLEVYN Dressing’s PIP evidence compendium.
31817. Available at:
https://smith-nephew.stylelabs.cloud/api/public/content/allevyn-dressings-pip-compendium-2021?v=f6cfe376
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people’s bodies and their self-belief
by using technology to take the limits off living. We call this
purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission
every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Sports Medicine & ENT and
Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.5 billion in 2023.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram
or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that
may or may not prove accurate. For example, statements regarding
expected revenue growth and trading profit margins, market trends
and our product pipeline are forward-looking statements. Phrases
such as "aim", "plan", "intend", "anticipate", "well-placed",
"believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown
risks, uncertainties and other important factors that could cause
actual results to differ materially from what is expressed or
implied by the statements. For Smith+Nephew, these factors include:
conflicts in Europe and the Middle East, economic and financial
conditions in the markets we serve, especially those affecting
healthcare providers, payers and customers; price levels for
established and innovative medical devices; developments in medical
technology; regulatory approvals, reimbursement decisions or other
government actions; product defects or recalls or other problems
with quality management systems or failure to comply with related
regulations; litigation relating to patent or other claims; legal
and financial compliance risks and related investigative, remedial
or enforcement actions; disruption to our supply chain or
operations or those of our suppliers; competition for qualified
personnel; strategic actions, including acquisitions and disposals,
our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; relationships with healthcare
professionals; reliance on information technology and
cybersecurity; disruptions due to natural disasters, weather and
climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation
regulations; effects of foreign exchange volatility; and numerous
other matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with the
U.S. Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith+Nephew's most
recent annual report on Form 20-F, which is available on the SEC’s
website at www. sec.gov, for a discussion of certain of these
factors. Any forward-looking statement is based on information
available to Smith+Nephew as of the date of the statement. All
written or oral forward-looking statements attributable to
Smith+Nephew are qualified by this caution. Smith+Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in
Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain
marks registered in US Patent and Trademark Office.
Smith & Nephew (LSE:SN.)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Smith & Nephew (LSE:SN.)
Gráfica de Acción Histórica
De May 2023 a May 2024